Frederik Barkhof

157.1k total citations · 26 hit papers
1.4k papers, 88.8k citations indexed

About

Frederik Barkhof is a scholar working on Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging and Psychiatry and Mental health. According to data from OpenAlex, Frederik Barkhof has authored 1.4k papers receiving a total of 88.8k indexed citations (citations by other indexed papers that have themselves been cited), including 595 papers in Pathology and Forensic Medicine, 434 papers in Radiology, Nuclear Medicine and Imaging and 393 papers in Psychiatry and Mental health. Recurrent topics in Frederik Barkhof's work include Multiple Sclerosis Research Studies (588 papers), Dementia and Cognitive Impairment Research (361 papers) and Advanced Neuroimaging Techniques and Applications (239 papers). Frederik Barkhof is often cited by papers focused on Multiple Sclerosis Research Studies (588 papers), Dementia and Cognitive Impairment Research (361 papers) and Advanced Neuroimaging Techniques and Applications (239 papers). Frederik Barkhof collaborates with scholars based in Netherlands, United Kingdom and United States. Frederik Barkhof's co-authors include Philip Scheltens, Serge A.R.B. Rombouts, Chris H. Polman, Wiesje M. van der Flier, Jeroen J.G. Geurts, Cornelis J. Stam, Massimo Filippi, Hugo Vrenken, Jessica S. Damoiseaux and Ludwig Kappos and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Frederik Barkhof

1.4k papers receiving 87.0k citations

Hit Papers

Consistent resting-state networks across healthy su... 1992 2026 2003 2014 2006 2010 2001 1992 2007 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Consistent resting-state networks across healthy subjects
    2006 3.4k citations Frederik Barkhof, Philip Scheltens et al. profile →
  2. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
    2010 1.6k citations Frederik Barkhof, Xavier Montalbán et al. profile →
  3. A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT
    2001 1.4k citations Frederik Barkhof, Franz Fazekas et al. profile →
  4. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.
    1992 1.3k citations Philip Scheltens, Frederik Barkhof et al. profile →
  5. Reduced resting-state brain activity in the “default network” in normal aging
    2007 968 citations Frederik Barkhof, Philip Scheltens et al. profile →
  6. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis
    1997 946 citations Frederik Barkhof Brain profile →
  7. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging
    1993 787 citations Philip Scheltens, Frederik Barkhof et al. profile →
  8. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
    2001 757 citations Massimo Filippi, Frederik Barkhof et al. profile →
  9. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: An fMRI study
    2005 606 citations Frederik Barkhof, Philip Scheltens et al. profile →
  10. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability
    1999 586 citations Paul van der Valk, CH Polman et al. profile →
  11. Cortical lesions in multiple sclerosis
    1999 578 citations Frederik Barkhof et al. Brain profile →
  12. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations
    2010 570 citations Alexandra Seewann, Wiesje M. van der Flier et al. profile →
  13. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
    2016 564 citations Massimo Filippi, Maria A. Rocca et al. profile →
  14. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
    1996 562 citations Frederik Barkhof, C. Polman et al. Neurology profile →
  15. Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
    2006 561 citations Katherine Miszkiel, Frederik Barkhof et al. profile →
  16. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
    2011 538 citations Ludwig Kappos, Frederik Barkhof et al. profile →
  17. The clinico-radiological paradox in multiple sclerosis revisited
    2002 532 citations Frederik Barkhof profile →
  18. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis
    1998 519 citations Philip Scheltens, CH Polman et al. Neurology profile →
  19. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
    2006 501 citations Ludwig Kappos, Gilles Edan et al. Neurology profile →
  20. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
    2021 411 citations Frederik Barkhof et al. profile →
  21. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
    2017 411 citations Philip Scheltens, Frederik Barkhof et al. Alzheimer s Research & Therapy profile →
  22. Association between pathological and MRI findings in multiple sclerosis
    2012 377 citations Massimo Filippi, Maria A. Rocca et al. profile →
  23. Arterial Spin Labeling Perfusion of the Brain: Emerging Clinical Applications
    2016 365 citations Frederik Barkhof et al. profile →
  24. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines
    2019 348 citations Massimo Filippi, Paolo Preziosa et al. Brain profile →
  25. Gut Microbiota Composition Is Related to AD Pathology
    2022 149 citations Charlotte E. Teunissen, Frederik Barkhof et al. profile →
  26. Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data
    2021 142 citations Arman Eshaghi, Ferrán Prados et al. profile →

Peers

Frederik Barkhof
Massimo Filippi Italy
Paul M. Matthews United Kingdom
Alan J. Thompson United Kingdom
Mark Jenkinson United Kingdom
Gıancarlo Comı Italy
Nicola De Stefano Italy
Franz Fazekas Austria
Henrik Zetterberg Sweden
Kaj Blennow Sweden
Philip Scheltens Netherlands
Massimo Filippi Italy
Frederik Barkhof
Citations per year, relative to Frederik Barkhof Frederik Barkhof (= 1×) peers Massimo Filippi

Countries citing papers authored by Frederik Barkhof

Since Specialization
Citations

This map shows the geographic impact of Frederik Barkhof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederik Barkhof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederik Barkhof more than expected).

Fields of papers citing papers by Frederik Barkhof

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frederik Barkhof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederik Barkhof. The network helps show where Frederik Barkhof may publish in the future.

Co-authorship network of co-authors of Frederik Barkhof

This figure shows the co-authorship network connecting the top 25 collaborators of Frederik Barkhof. A scholar is included among the top collaborators of Frederik Barkhof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frederik Barkhof. Frederik Barkhof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bos, Len, James H. Cole, Eva Strijbis, et al.. (2025). Repeatability and reproducibility of brain age estimates in multiple sclerosis for three publicly available models. Neuroimage Reports. 5(2). 100252–100252.
2.
Venkatraghavan, Vikram, Wiesje M. van der Flier, Yolande A.L. Pijnenburg, et al.. (2025). Enlarged cavum septum pellucidum as a neuroimaging signature of head impact exposure. Brain Communications. 7(2). fcaf085–fcaf085. 1 indexed citations
3.
Moccia, Marcello, Alessia Bianchi, Alan J. Thompson, et al.. (2025). Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis. Annals of Clinical and Translational Neurology. 12(10). 2077–2085.
4.
Bollack, Ariane, Lyduine E. Collij, Mahnaz Shekari, et al.. (2024). The Centiloid scale: guidance on clinical context of use from the AMYPAD Consortium. Alzheimer s & Dementia. 20(S2). 1 indexed citations
5.
Groot, Colin, H. Stevie Tan, Jurre den Haan, et al.. (2024). Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic. Alzheimer s Research & Therapy. 16(1). 190–190. 4 indexed citations
6.
Hoogland, Jeroen, Leonie N.C. Visser, Argonde C. van Harten, et al.. (2024). Predicting Cognitive Decline in Amyloid-Positive Patients With Mild Cognitive Impairment or Mild Dementia. Neurology. 103(3). 7 indexed citations
7.
Backes, Walter H., Josephine Barnes, Frederik Barkhof, et al.. (2023). Assessment of Microvascular Disease in Heart and Brain by MRI: Application in Heart Failure with Preserved Ejection Fraction and Cerebral Small Vessel Disease. Medicina. 59(9). 1596–1596. 6 indexed citations
8.
Martin, Sophie, et al.. (2023). Interpretable machine learning for dementia: A systematic review. Alzheimer s & Dementia. 19(5). 2135–2149. 69 indexed citations
9.
Brownlee, Wallace, Dan Altmann, Ferrán Prados, et al.. (2019). Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain. 142(8). 2276–2287. 116 indexed citations
10.
Hagens, Marloes, Jessica Burggraaff, Iris D. Kilsdonk, et al.. (2018). Three-Tesla MRI does not improve the diagnosis of multiple sclerosis. Neurology. 91(3). e249–e257. 31 indexed citations
11.
Preziosa, Paolo, Maria A. Rocca, Manfredo Atzori, et al.. (2014). Structural MRI correlates of cognitive impairment in patients with multiple sclerosis: A Multicenter Study. UCL Discovery (University College London). 4 indexed citations
12.
Sombekke, Madeleine H, Mike P. Wattjes, Lisanne J. Balk, et al.. (2012). Spinal cord lesions in patients with clinically isolated syndrome. Neurology. 80(1). 69–75. 105 indexed citations
13.
Ascherio, Alberto, Kassandra L. Munger, Chantal Simon, et al.. (2012). Serum 25-hydroxyvitamin D concentrations among patients in BENEFIT predicts conversion to multiple sclerosis, MRI lesions, and brain volume loss. UCL Discovery (University College London). 2 indexed citations
14.
Seewann, Alexandra, Hugo Vrenken, Evert‐Jan Kooi, et al.. (2011). Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosis. Multiple Sclerosis Journal. 17(10). 1202–1210. 88 indexed citations
15.
Geurts, Jeroen J.G., Stefan D. Roosendaal, Massimiliano Calabrese, et al.. (2011). Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology. 76(5). 418–424. 237 indexed citations
16.
Kappos, Ludwig, Xavier Montalbán, C. Polman, et al.. (2011). Long-term effect of early treatment with interferon-beta-1b after a first clinical event suggestive of multiple sclerosis: 8-year observational extension of the phase 3 BENEFIT trial. UCL Discovery (University College London). 1 indexed citations
17.
Barkhof, Frederik, Hanneke E. Hulst, Jelena Drulović, et al.. (2010). Ibudilast in relapsing-remitting multiple sclerosis. Neurology. 74(13). 1033–1040. 109 indexed citations
18.
Montalbán, Xavier, Mar Tintoré, Josephine Swanton, et al.. (2010). MRI criteria for MS in patients with clinically isolated syndromes. Neurology. 74(5). 427–434. 179 indexed citations
19.
Kappos, Ludwig, C.H. Polman, M. S. Freedman, et al.. (2005). Betaferon in newly emerging multiple sclerosis for initial treatment (BENEFIT): First results. UCL Discovery (University College London). 3 indexed citations
20.
Barkhof, Frederik, Giorgos B. Karas, & Marianne AA van Walderveen. (2000). T1 HYPOINTENSITIES AND AXONAL LOSS. Neuroimaging Clinics of North America. 10(4). 739–752. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Massimo Filippi Breakdown of academic impact, for papers by Paul M. Matthews Breakdown of academic impact, for papers by Alan J. Thompson Breakdown of academic impact, for papers by Mark Jenkinson Breakdown of academic impact, for papers by Gıancarlo Comı Breakdown of academic impact, for papers by Nicola De Stefano Breakdown of academic impact, for papers by Franz Fazekas Breakdown of academic impact, for papers by Henrik Zetterberg Breakdown of academic impact, for papers by Kaj Blennow Breakdown of academic impact, for papers by Philip Scheltens
Rankless by CCL
2026